Leveraging GOLD and Discovery Studio for CNS-targeted Drug Discovery

Metabotropic glutamate receptors (mGluRs) play a crucial role in modulating excitatory neurotransmission in the central nervous system (CNS), making them promising drug targets for neurological and psychiatric disorders. We applied structure-based drug design methods in BIOVIA Discovery Studio and molecular docking with GOLD to develop a highly potent and selective mGlu2 receptor agonist. We also explored the biological significance of mGlu2/mGlu3 selectivity, its impact on CNS pharmacology, and how computational tools can help predict ligand-receptor interactions.

Whether you are a medicinal chemist, computational biologist, or neuroscientist, don’t miss the opportunity to explore the impact of advanced molecular modeling in accelerating CNS-targeted drug discovery.

Webinar highlights:

• Gain insights into docking methodologies, induced-fit modeling, and key residue interactions that drive subtype selectivity.
• Learn how computational modeling guides the development of selective receptor agonists.
• Discover how integrating advanced molecular modeling tools are driving precision in neuropharmacology.

​​​​​​​Register now to watch the replay!